Медицинский совет, 2021 Introduction. Currently, a number of pharmacoeconomic studies describing use of erythropoietin stimulating agent (ESA) in cancer patients with anemia have been published, however, most of the publications on this topic are foreign.
I. S. Krysanov +2 more
doaj +1 more source
Randomized trial comparing proactive, high-dose versus reactive, low-dose intravenous iron supplementation in hemodialysis (PIVOTAL) : Study design and baseline data [PDF]
, 2018 Background: Intravenous (IV) iron supplementation is a standard maintenance treatment for hemodialysis (HD) patients, but the optimum dosing regimen is unknown.
Anker, Stefan D. +12 more
core +4 more sources
Extended dosing of darbepoetin alfa in peritoneal dialysis patients
BMC Nephrology, 2011 Background Anemia is common among peritoneal dialysis (PD) patients, and most patients require erythropoiesis-stimulating agents (ESA) to maintain their hemoglobin concentrations within current guideline recommendations. Darbepoetin alfa is an ESA with a
Bridges Ian +6 more
doaj +1 more source
Darbepoetin alfa: An Effective Treatment with Flexible and Simplified Dosing for Anemia in Patients with Cancer [PDF]
, 2007 Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/90361/1/phco.27.3.434 ...
Natale, James J., Stevenson, James G.
core +1 more source
Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF) [PDF]
, 2014 Aim<p></p> To describe the baseline characteristics and treatment of the patients randomized in the PARADIGM-HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and morbidity in Heart Failure) trial, testing ...
Adel R. Rizkala +11 more
core +3 more sources
BMC Cancer, 2010 Background Chemotherapy-induced anemia (CIA) is responsive to treatment with erythropoiesis-stimulating agents (ESAs) such as darbepoetin alfa. Administration of ESAs on a synchronous schedule with chemotherapy administration could benefit patients by ...
Silberstein Peter +7 more
doaj +1 more source
Український Журнал Нефрології та Діалізу, 2015 The article describes the ways to cost optimization of anemia treatment CKD - HD patients. Aims. dinical and economic analysis treatment of Anemia CKD VHD PTS with using long action Erythropoiesis Stimulating Agents (ESA). Methods.
M. Kolesnyk, N. Bezdetko, V. Novakivskyy
doaj +1 more source
The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions. [PDF]
, 2014 Anemia is a common finding in congestive heart failure (CHF) and is associated with an increased mortality and morbidity. Several conditions can cause depression of erythroid progenitor cells: reduction of iron absorption and reuptake, decreased bone ...
De Gori, C +6 more
core +1 more source
Frontiers in Pharmacology, 2022 Background: Vadadustat is a novel drug for treating anemia patients with chronic kidney disease (CKD), but its effect and safety remain uncertain. This study aimed to summarize the evidence for vadadustat in the treatment of CKD patients with anemia ...
Limei Xiong +8 more
doaj +1 more source
Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study [PDF]
, 2016 Background Since 2007 biosimilars of erythropoiesis-stimulating agents (ESAs) are available on the Italian market. Very limited post-marketing data exist on the comparative effectiveness of biosimilar and originator ESAs.
Alibrandi, A. (Angela) +12 more
core +6 more sources